CD19 and plasma cell myeloma: Like the anti-BCMA/CD19 CAR T cells in systemic lupus erythematosus, we observed a lower incidence of grade 3 or worse hematologic toxicities (except for lymphopenia mainly due to chemotherapy) comparing our previous CAR T-cell trials in multiple myeloma.16